Compare LIND & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | NKTR |
|---|---|---|
| Founded | 1979 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2011 | 1996 |
| Metric | LIND | NKTR |
|---|---|---|
| Price | $25.80 | $69.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $22.25 | ★ $146.67 |
| AVG Volume (30 Days) | ★ 773.1K | 509.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.97 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | $10.98 | N/A |
| Revenue Next Year | $6.98 | N/A |
| P/E Ratio | $362.21 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $11.37 | $33.40 |
| 52 Week High | $35.00 | $109.00 |
| Indicator | LIND | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 44.65 |
| Support Level | $24.79 | $70.24 |
| Resistance Level | $30.00 | $76.49 |
| Average True Range (ATR) | 1.26 | 2.88 |
| MACD | -0.64 | -0.31 |
| Stochastic Oscillator | 10.99 | 15.34 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.